Amina Zoubeidi

Assistant Professor, Department of Urologic Sciences
Degrees / Designations 

University Mohamed V, Morocco BSc 1990-1994 Biology
University. du Quebec, Montreal MSc 1995-1998 Biology
University of Montreal PhD 1998-2004 Biochemistry

2003 - 2004 Post-doctoral Fellow, McGill University, Montreal
2005 - 2009 Post-doctoral Fellow, Vancouver Prostate Centre
2009 - Research Scientist, Vancouver Prostate Centre (as of July 1, 2009)
2009 - Assistant Professor, Dept. of Urologic Sciences, University of British Columbia

(604) 875-4111 # 68880
Mailing Address 
2660 Oak Street Vancouver BC V6H 3Z6, Canada


Academic Appointment 
Assistant Professor
Disorders and Conditions 

Dr Zoubeidi major research focus is to uncover molecular mechanisms of prostate cancer progression to the castrate-resistant stage and metastatic disease with a special interest on elucidating mechanisms of epithelial mesenchymal transition. She elucidates diverse mechanisms involving stress activated proteins, Hsp27, clusterin, and tyrosine kinases Lyn and Fer in androgen independent progression. She recently developed pre-clinical models of MDV3100 resistant tumors and cell lines and studying mechanisms of resistance to MDV3100. She has an extensive expertise in cell signaling, molecular and cellular biology and in vivo efficacy studies. She holds a Michel Smith Foundation for Health Research, Career development award (2012-2021), a merit award for academic achievement, University of British Columbia (2011), the New Investigator Award, Terry Fox Research Institute (2010-2014),a new Investigator Award, Prostate Cancer Foundation (USA) (2010-2013), and multiple research context awards including first prize, Research award, American Urological Association (2008), first prize, Research award, Northwest Urological Society (2007) and AACR- Brigid G. Leventhal Scholar in Cancer Research Award (2007) and a dean’s honor list, PhD thesis, Université de Montréal (2005) among others.

Current Projects 

1. Rational Design of targeting Hsp27 in EMT and metastatic prostate cancer
2. Defining the role of Lyn kinase in prostate cancer progression to CRPC
3. Rationale targeting HER2 and AR to prevent emergence of MDV3100 resistance
4. Persistent androgen receptor activation after maximum androgen blockade
5. Targeting adaptive pathways in metastatic castration resistant prostate cancer (Competitive).